In a report issued on January 19, Eric Coldwell from Robert W. Baird maintained a Hold rating on CVS Health (CVS – Research Report), with a price target of $110.00. The company’s shares closed last Thursday at $105.32, close to its 52-week high of $111.25.
According to TipRanks.com, Coldwell is a 5-star analyst with an average return of 13.5% and a 61.5% success rate. Coldwell covers the Healthcare sector, focusing on stocks such as Quest Diagnostics, AmerisourceBergen, and Cardinal Health.
CVS Health has an analyst consensus of Strong Buy, with a price target consensus of $117.53, which is a 12.4% upside from current levels. In a report issued on February 9, BMO Capital also maintained a Hold rating on the stock with a $120.00 price target.
Based on CVS Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $76.6 billion and net profit of $1.31 billion. In comparison, last year the company earned revenue of $69.55 billion and had a net profit of $973 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Headquartered in Rhode Island and founded in 1963, CVS Health Corp. is a healthcare company in the U.S. that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands.
Read More on CVS:
- Robert W. Baird Maintains a Hold Rating on Trex Company (TREX)
- Robert W. Baird Maintains a Hold Rating on Fortune Brands (FBHS)
- Robert W. Baird Maintains Their Buy Rating on Syneos Health (SYNH)
- Quest Diagnostics (DGX) Gets a Hold Rating from Robert W. Baird
- Robert W. Baird Believes AmerisourceBergen (ABC) Won’t Stop Here